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ABSTRACT

A Clinical Trial of Clonidine and Naltrexone
for the Outpatient Treatment of Heroin Withdrawal

Mark David Topazian

1985
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1
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test

score

score
and

and

patient

INTRODUCTION

Physicians have long sought to alleviate the symptoms of
opioid withdrawal.

The opioid withdrawal syndrome,

together with

the phenomenon of tolerance, makes manifest "opioid dependence"
(APA 1980), defined as the biological changes or "neuroadapta¬
tion"

(Edwards 1981) that occur following chronic opioid adminis¬

tration.

Opioid abuse, characterized by inability to reduce or

stop opioid use despite consequent impairment of social or occu¬
pational functioning (APA 1980),
dependence.

is often accompanied by opioid

Successful withdrawal treats dependence, but does

not prevent relapse (and hence is not a sufficient treatment of
opioid abuse or "addiction").

Nevertheless, withdrawal is an im¬

portant element in the therapy of addiction,

and is the first

step towards definitive treatment of opioid abuse (except for pa¬
tients entering methadone maintenance).

Since the late nineteenth century a variety of withdrawal
treatments have been advocated,
mine intoxication,

including belladonna or scopala-

sodium thiocyanate,

ECT, and "hibernation therapy"

"bromide sleep treatment,"

(Kleber 1982).

These methods have

been endorsed, practiced, and then discarded when they proved to
be ineffective and often more dangerous than the condition they
set out to alleviate.

Since 1948, methadone, a long acting

opioid agonist, has been used as a substitute opioid that is ad-

-
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ministered to the opioid dependent patient in gradually decreas¬
ing daily doses.

Methadone is usually administered over five to

twelve days for the treatment of heroin withdrawal (Kleber 1982).
This method attenuates symptoms while prolonging the course of
withdrawal.

Methadone treatment of heroin withdrawal has been tried in
both inpatient and outpatient settings, and over various time
courses,

in an attempt to improve the efficacy of therapy.

Wil¬

son, et al administered a ten day course of methadone to ten in¬
patients and thirty outpatients.

One inpatient (10%) and six

outpatients (20%) completed the protocol, and no inpatients (0%)
and two outpatients (7%) remained drug-free following treatment.
The authors concluded that there was no significant difference
between approaches (Wilson 1975).

Outpatient trials employing

seven day and ninety day protocols have reported successful with¬
drawal rates of 32% and 13%,
1974).

respectively (Silsby 1974)

(Wilson

At six months, 9.5% and 0% of patients in these two stud¬

ies were drug free.

Dorus, et al compared an FDA-mandated twen¬

ty-one day methadone taper with an eighty-four day taper under
double blind conditions.

They found that the more gradual taper

was more successful, resulting in a 35% rate of successful detox¬
ification and abstinence for one week.

One year later,

16% of

the patients that underwent the eighty-four day taper were absti¬
nent (Dorus 1981)

(Dorus 1982).

None of the patients in their

twenty-one day group remained opiate free for even ninety days.
A slower methadone taper decreases the symptoms of withdrawal for

3

both heroin users (Dorus 1981) and methadone maintained patients;
the latter achieved a 53% rate of successful detoxification with
a thirty week methadone taper (Senay 1977).
innovations,

But despite protocol

these studies have concluded that methadone treat¬

ment of heroin dependence is successful in less than 40% of cas¬
es, and is an even less successful treatment of heroin abuse.

Investigators have continued to search for methods of allevi¬
ating the opioid withdrawal syndrome that are more rapid and more
effective than methadone detoxification, and that do not involve
use of opioid agonists or other addicting substances.

In 1964

Berle and Nyswander treated withdrawal over two to four weeks
with a combination of meprobamate, chlorpromazine, and glutethimide; fifty-three of their two hundred sixty-eight patients (20%)
withdrew successfully.

Opiate antagonists have been used to

treat withdrawal by shortening the length of the abstinence syn¬
drome (Blachly 1975)

(Kuiland 1975)

(Resnick 1977).

edly compressing the time of withdrawal,

While mark¬

this treatment intensi¬

fied withdrawal symptoms, even when symptomatic medications such
as atropine and diazepam were added.

Recently, clonidine, an im¬

idazoline alpha-2 adrenergic agonist used as an antihypertensive,
has been demonstrated to effectively suppress the signs and symp¬
toms of opioid withdrawal, with reported success rates as high as
80% with methadone withdrawal (Charney 1981) and 36% with heroin
withdrawal (Washton 1980b).

-
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While opioid withdrawal affects brain function in a variety of
ways (Redmond 1984), perhaps its most prominent effect is on cen¬
tral nervous system noradrenergic function.

Clonidine alters the

opioid withdrawal syndrome by modulating central nervous system
noradrenergic activity.

In 1959 Gunne demonstrated that total

brain norepinephrine (NE) decreased during opioid withdrawal,
suggesting that withdrawal was associated with increased NE re¬
lease (Gunne 1959).

Vasques,

in 1974,

found that chronic mor¬

phine administration led to a disuse hypersensitivity in central
noradrenergic systems (Vasques 1974).
rate of the locus coeruleus (LC),
gic nucleus (Korf 1974)

Opioids depress the firing

the largest central noradrener¬

(Bird 1977); prolonged opioid administra¬

tion and concommitant LC depression result in enhanced numbers of
alpha-2 and beta adrenergic binding sites in LC projection areas
(Hamburg 1981)

(Llorens 1978).

Opioid withdrawal is associated

with central noradrenergic hyperactivity as reflected by de¬
creased brain norephinephrine levels (Gunne 1959) and increased
norepinephrine metabolite levels (Crawley 1979).

Clonidine, an

alpha adrenergic agonist that diminishes NE release by binding
presynaptically to alpha-2 receptors,

reverses the increased no¬

repinephrine turnover seen during morphine withdrawal in rats
(Laverty 1980).

Using single-cell recording and microiontophoretic techniques,
Aghajanian investigated the role of clonidine and the LC in
opioid withdrawal.

He found that naloxone increased LC activity

in morphine dependent rats but not in control rats.

5

Using con-

trol rats, he subsequently demonstrated that both morphine and
clonidine suppress noradrenergic activity in the LC.

Naloxone

abolishes morphine-induced suppression, but does not abolish clo¬
nidine ' s suppressive effect.

Piperoxane abolishes clonidine's

suppressive effect but does not abolish morphine's suppressive
effect.

These data indicate that morphine acts at the LC by

binding to opioid receptors, while clonidine's actions are medi¬
ated by alpha adrenergic receptors.

Finally,

in morphine depen¬

dent rats, he demonstrated that both morphine and clonidine could
suppress naloxone-induced increases in LC activity; naloxone
could override morphine's suppressive effect, but could not over¬
ride clonidine's suppressive effect (Aghajanian 1978).

In mor¬

phine dependent rats, clonidine attenuates naloxone-precipitated
NE turnover in a dose related fashion (Laverty 1979).

These data

established that opioid withdrawal provokes central noradrenergic
hyperactivity, and that this hyperactivity can be reversed not
only by morphine acting at opioid receptors, but by clonidine
acting at alpha-2 receptors in the LC.
effect is not affected by naloxone.

Furthermore, clonidine's

Thus a model of overlapping

receptor populations in the LC has emerged that accounts for clo¬
nidine ' s antiwithdrawal effects.

Clonidine has been shown to alter the symptoms and physiologi¬
cal signs of opioid withdrawal in animals.
rats,

In morphine dependent

clonidine inhibits naloxone-induced escape attempts and

"wet body shakes"

(Tseng 1975), prevents weight loss and suppres¬

sion of conditioned behavior (Sparber 1978), and antagonizes na-
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loxone-induced increases in mean arterial pressure (Buccafusco
1983).

Redmond correlated stimulation of the LC with behavioral

observations in monkeys (Redmond 1976)
1978)

(Redmond 1977)

(Redmond

(Redmond 1981), suggesting that the central noradrenergic

axis in large part mediates opioid withdrawal.

Clonidine has,

in fact, been used successfully to ameliorate

withdrawal symptoms and to detoxify methadone maintained patients
(Gold 1978a)
1980b).

(Uhde 1980)

(Gold 1980)

(Washton 1980a)

(Washton

Success rates of 70% (Washton 1980b) and 80% (Charney

1981) have been reported in trials using clonidine for treatment
of abrupt methadone withdrawal.

In double blind, placebo cont¬

rolled studies clonidine has been shown to be more effective than
placebo (Gold 1978b) and as effective as a twenty day methadone
taper (Washton 1981) in alleviating methadone withdrawal symptoms
and enabling complete detoxification.

Clonidine treatment of

heroin withdrawal is less well studied.

Washton, who treated

both heroin users and methadone maintained patients with cloni¬
dine,

found that four of eleven (36%) heroin users and thirty-

five of forty-nine (70%) methadone patients successfully remained
opioid free for ten days (Washton 1980b).

Clonidine treatment of

heroin withdrawal takes seven to eight days, while methadone
withdrawal requires ten to fourteen days.

Clonidine has been used to treat withdrawal in an outpatient
setting.

At Yale, over one hundred methadone maintained patients

have been withdrawn.using clonidine on an outpatient basis with-
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out medical complications.
restlessness,

The withdrawal symptoms of anxiety,

insomnia, and muscular aching are most refractory

to clonidine and are reported to some degree by the majority of
patients.

The primary acute side effects of clonidine therapy are seda¬
tion and hypotension; as insomnia and hypertension are symptoms
of withdrawal, neither side effect routinely interferes with
therapy.
tients,

Washton reported that, among a series of seventy outpa¬
six "experienced unacceptable dizziness and/or sedation

while taking only 0.3 mg/day of clonidine"

(Washton 1980).

Clo¬

nidine doses given to outpatients at Yale have been tapered or
held if diastolic blood pressure dropped below 55, or systolic
pressures were lower than 85.

Charney, et al reported that,

among twenty-five inpatients receiving peak clonidine doses of 16
microg/kg/day,

standing blood pressure was reduced by as much as

17 +-13/8 +-11, without "producing clinical problems"

(Charney

1981).

One drawback of both methadone taper and clonidine treatment
is the time required to complete therapy.

Long duration of mild

withdrawal symptoms affords greater opportunity for treatment
failure, with patients resuming opioid use.

Thus clonidine has

been paired with opioid antagonists that precipitate an abrupt
opioid withdrawal syndrome (Riordan 1980),

in an effort to short¬

en the duration of withdrawal while maintaining clonidine's bene¬
ficial effects.

The first clinical trial of clonidine in combi-
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nation with an antagonist used repeated naloxone injection
(Riordan 1980); a second utilized naltrexone, an antagonist that
is administered orally (Charney 1982).

Naltrexone is a potent,

long-acting narcotic antagonist used

clinically to help maintain patients opioid-free after detoxifi¬
cation from methadone.
onist,

that is,

It is an essentially pure narcotic antag¬

it does not possess "agonistic" or morphine-like

properties characteristic of some other narcotic antagonists
(Martin 1973).

In the absence of narcotics or agonist effects it

exhibits essentially no pharmacologic activity (Hollister 1981).
Former addicts beginning naltrexone report side effects indistin¬
guishable from those of placebo, after a ten day period marked by
loss of appetite and tiredness in 20% of subjects (Brahen 1977).
There is some evidence that patients maintained on naltrexone
have less subjective craving for heroin because of naltrexone
therapy (Sideroff 1978)

(Judson 1981).

In the presence of physical dependence on narcotics, naltrex¬
one and other opioid antagonists induce an abrupt withdrawal syn¬
drome (Blachly 1975)

(Kuiland 1975)

central noradrenergic activity.

(Resnick 1977) by altering

Naloxone blocks opioid receptors

on the LC and so increases LC firing rates in morphine-dependent
animals (Aghajanian 1978) and rapidly reverses morphine-induced
increases in the number of brain alpha-2 and beta adrenergic
binding sites (Hamburg 1981)

(Cedarbaum 1977).

This rapid change

in binding site numbers may account for the ability of naltrexone

-
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to shorten the time course of the opioid withdrawal syndrome
(Charney 1982).

Clonidine and naltrexone have been used in combination on an
inpatient basis to induce abrupt and safe withdrawal from metha¬
done over six days (Charney 1982).

Ten of eleven patients who

began a study conducted at the Connecticut Mental Health Center
successfully detoxified from methadone; the eleventh left the
study on the second day, after receiving the first dose of nal¬
trexone and experiencing some discomfort.
one regimen had three stages.

The clonidine-naltrex-

On day 1, opioids were withheld

and only clonidine given; on days 2 and 3, naltrexone was intro¬
duced and increasingly higher doses were given in combination
with increasing doses of clonidine; and on days 4,5 and 6 naltre¬
xone doses plateaued at maintenance levels while clonidine doses
fell to zero.

The first stage, day 1, allowed time to observe

the patients response to and tolerance of clonidine.

During the

second stage withdrawal was precipitated and symptoms ameliorated
with higher doses of clonidine (2.9 +.6 mg/day on day 3).

.8 mg/day on day 2, 2.3 +-

Clonidine doses were increased as needed to

suppress withdrawal symptoms as rated by an abstinence rating
scale.

Clonidine effectively suppressed the symptoms naltrexone

usually induces in a withdrawing addict; when compared to a pre¬
vious study that used clonidine alone to treat withdrawal (Char¬
ney 1981) patient discomfort was found to be lower with the clonidine-naltrexone regimen.

During the third stage, naltrexone

doses no longer elicited discomfort, clonidine doses fell off

10

rapidly, and no clonidine was required after day 5 or 6.

Pa¬

tients wishing to be maintained on naltrexone continued to re¬
ceive maintenance doses of naltrexone without withdrawal symptoms
or need for clonidine.

Thus naltrexone induction took place as a

part of withdrawal.

Although this technique appeared to be effective on an inpa¬
tient basis,

it was not evident that it could be done safely and

effectively on an outpatient basis.

Potential drawbacks of out¬

patient treatment include the danger of hypotension and sedation
sometimes seen with clonidine therapy,

the possibility of concur¬

rent illicit drug use, and patient compliance with clonidine dos¬
age schedules.

Nevertheless, outpatient treatment of opioid

withdrawal is desirable.

Clearly, outpatient treatment is less

expensive than inpatient treatment,
limited medical resources.

and places less strain on

Outpatient therapy allows patients

with jobs and other responsibilities to continue their employ¬
ment.

Since it does not offer the useful but temporary shelter

from the "drug culture" that inpatient treatment gives,

relapse

and treatment failure may be more likely in the outpatient set¬
ting.

Long term relapse rates may not differ, however,

since if

the addict can withdraw from the social accoutrements of drug use
while withdrawing from opioids, his prognosis may be better.

The

study described in this paper was designed to investigate the ef¬
ficacy and saftey of outpatient treatment with clonidine and nal¬
trexone .
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Rapid outpatient detoxification, with simultaneous naltrexone
induction,

is desirable not only for patients maintained on me¬

thadone but for "street addicts" who use heroin and other opioids
illicitly.

This study was designed to enroll both types of

opioid users.

The degree of a street addict's opioid dependence

is difficult to determine because of unreliable histories and the
inconstant opioid concentrations found in street drugs.

(For

this reason, all clonidine research studies at Yale have been
performed on methadone maintained patients whose daily intake of
opioids was known.)

As mentioned above, Washton and associates

used clonidine on an outpatient basis with heroin addicts and
found that 36% completed detoxification; they estimated depen¬
dence based on dollars spent on heroin per day, and found that
patients with high estimates tended to be dissatisfied with the
efficacy of the experimental regimen (Washton 1980).

To avoid

the subjectivity of this approach, we studied heroin addicts by
quantifying their degree of physical dependence with a naloxone
challenge test.

From 3% to 33% of patients receiving a naloxone

challenge in previous reports have had a negative test (Blachly
1973)

(Judson 1980),

indicating that they were not opioid depen¬

dent and did not need methadone maintenance or a pharmacological
regimen for withdrawal.

The test we used, described by Wang and

his associates in 1974 and modified in 1977 and 1982 (Wang 1974)
(Weisen 1977)

(Wang 1982),

rates objective symptoms of withdraw¬

al, giving more weight to symptoms that appear rapidly.

Weisen

has demonstrated a significant correlation between test score and
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appropriate initial methadone maintenance doses in 210 subjects
(r=.77, p<0.01)

(Weisen 1977), and this test can now be used to

assess patients seeking methadone maintenance in order to assign
initial methadone doses.

The test accurately quantifies the se¬

verity of a patient's opioid dependence.

13

METHOD

SUBJECTS

The patient sample comprised ten men and seven women treated
by the Substance Abuse Treatment Unit of the Connecticut Mental
Health Center, New Haven.

Mean age was 29.3 years (+-5.6) and

mean duration of opioid use was 7.4 years (+-4.9).
to be drawn from two populations.

Patients were

One group was to consist of

members in good standing of a methadone maintenance program,
maintained for at least three months and on a methadone dose of
20 to 25 mg for at least one week prior to entering the study.
Only one patient entered this treatment group.

The second group

consisted of self-professing opioid users who had not been en¬
rolled in a methadone maintenance program within the prior three
months.

Patients in this treatment group were required to under¬

go a naloxone challenge test.

Sixteen patients entered this

group during the duration of the study.

All used heroin; over

half of the sixteen abused other drugs as well.
travenous cocaine,

Four used in¬

five regularly purchased methadone, most

smoked marijuanana, and two abused benzodiazapenes.

All patients were in good health as evidenced by a medical
history, physical examination, CBC, urinalysis, EKG, and SMA-12
in the week prior to their inclusion in the study.
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All patients

gave informed written consent for their participation in the re¬
search protocol.

Candidates were ruled out based on the follow¬

ing exclusionary criteria:
1. Younger than 18 years or older than 45 years.
2. Systolic blood pressure greater than 165, or diastolic
pressure greater than 110, or ongoing medical treatment for
hypertension.
3. Current treatment for other medical conditions requiring
ongoing medication.
4. Treatment with tricyclic antidepressants, MAO inhib¬
itors, or phenothiazines during the two weeks prior to par¬
ticipation.
5. Allergy to imidazoline drugs.
6. History of acute or chronic active hepatitis, cardias
arrythmias,
50 bpm,

rheumatic fever,

sinus bradycardia of less than

renal or metabolic diseases.

7. Personal history of severe psychiatric disorder (e.g.,
major psychotic episode,

schizophrenia, psychotic depres¬

sion, bipolar affective disorders.)
8. Pregnancy.

(All women included in the study has a neg¬

ative B-HCG test within one week of inclusion in the study.)

During the week prior to participation in the study, all sub¬
jects completed the Beck Depression Inventory,

the SCL-90,

the

Spielberger State Anxiety Index, and the Rotter Internal/External
Locus of Control Scale.
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TREATMENT SCHEDULE

Patients received one day of clonidine followed by four to
five days of combination clonidine and naltrexone therapy.

Clo¬

nidine was administered t.i.d. with supplementary doses on days
1, 2, and 3.

Patients received naltrexone in four divided doses

on days 2 and 3, and then in one or two doses on day 4 and in one
dose on day 5. The treatment schedule was flexible, and was de¬
signed to produce minimum discomfort for the patient.

Patients came to clinic daily at 8-9 am to receive medication,
answer questionaires, and have their blood pressure monitored.
On the second and third days of the study patients were required
to remain in clinic from 8:30 am to 4:30 pm so that their with¬
drawal symptoms could be followed, naltrexone doses adjusted, and
supplementary clonidine given as indicated.

Patients were not

allowed to work on the second and third days, and were not al¬
lowed to drive on the first three days.

While in clinic, blood

pressures were monitored before, 60 minutes after, and 120 min¬
utes after each clonidine dose.

Patients took prescribed cloni¬

dine home with them (usually including a 0.1 to 0.2 mg "prn"
dose), but were required to return extra pills the following
morning.

Clonidine was given daily at 8-9 am, 2 pm, and 8 pm.
ter two doses could be taken at home.
received only clonidine.

The lat¬

On the first day patients

Subjects not entering the study from a

methadone maintenance program underwent a naloxone challenge test
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on the morning of the first day (see below).

On days 1, 2, and 3

additional doses were given as needed to suppress symptoms of
withdrawal; clonidine was given if the patient had 5 or more of
the 17 signs and symptoms of withdrawal included in our absti¬
nence rating scale.
was prescribed.

On days 4 and 5 no supplementary clonidine

No clonidine was required after day 6.

Cloni¬

dine doses were tapered or held if standing systolic blood pres¬
sure was less than 80 or diastolic pressure less than 60, or if
patients had orthostatic symptoms.

On day 2, naltrexone treatment was begun.
given at 9:30 am,

11:30 am,

The initial dose was 1 mg,

Oral doses were

2:30 pm and 4:30 pm on days 2 and 3.
increased by 1 mg increments on day 2

and by 3 mg increments on day 3 if the patient's score on the 17
point abstinence rating scale was less than 5 prior to the dose
of naltrexone.

On day 4 each patient received 50 mg of naltrex¬

one, a maintenance dose.

Initially this was administered in

three divided doses (10 mg at 8-9 am,

15 mg at noon , and 25 mg

at 5 pm), however 8 patients received the 50 mg in a single oral
dose at 8-9 am without adverse effects.

On day 5 (usually a Fri¬

day) patients received 150 mg naltrexone at 8-9 am, and then con¬
tinued to receive maintenance doses of naltrexone the following
week as part of the protocol.

Patients came to clinic on days 8,

10, and 12 to take 100 mg of naltrexone and to respond to rating
scales.
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Patients with NCT scores (see below) less than 20 in most cas¬
es tolerated naltrexone without symptoms, therefore we simplified
the naltrexone dosage schedule for our last patient.
naltrexone in two daily doses on days two and three,

He received
receiving

doses of 3 mg at 9:30 am and 7 mg at 2:30 pm on day 2, and 12 mg
at 9:30 am and 24 mg at 2:30 pm on day 3.

He did not complain of

symptoms in response to these doses (his NCT score was 12).

CONCOMMITANT MEDICATIONS

Patients were given chloral hydrate,
day at a time as indicated for insomnia.

1 gram p.o. q.h.s., one
For patients who did

not respond to chloral hydrate, or who experienced muscular ach¬
ing not adequately ameliorated by clonidine,

flurazepam 30 mg or

diazepam 10 mg was prescribed in place of chloral hydrate.

Daily urine samples were collected and analyzed to evaluate
use of illicit drugs.

NALOXONE CHALLENGE TEST (NCT)

Patients not entering the study from a methadone maintenance
program underwent a naloxone challenge test (NCT).

Patients were

cautioned not to self-administer opioids for eight hours prior to
the test, which took place between 8 am and 10 am on the morning
of their first day.

0.8 mg of naloxone was administered i.m. and

withdrawal symptoms rated using the scale of Wang, et al.
1974)

(Weisen 1977)

(Wang 1982).
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(Wang

Wang's rating scale is repro-

duced in Table 1.

If the patient's predicted score on Wang's 36

point scale was 9 or more after 10 minutes, clonidine was admin¬
istered immediately at 10 minutes.

If the patient's predicted

score was less than 9 after 10 minutes but greater than 9 after
20 minutes, clonidine was administered at 20 minutes.

If the pa¬

tient's score was less than 9 after 20 minutes but greater than 0
after 30 minutes, clonidine was given at 30 minutes.

Day 1 clo¬

nidine doses, based on NCT scores, are listed in Table 2.

Those

whose withdrawal symptoms were not adequately controlled by their
initial clonidine dose (score of greater than 5 on our abstinence
rating scale) received additional clonidine after 60 minutes.

Individuals whose score was 0 after 10 minutes of the NCT re¬
ceived a second injection of 0.8 mg naloxone i.m. and were ob¬
served and scored for withdrawal for the following thirty min¬
utes.

Individuals whose score was less than two 30 minutes after

having received a total of 1.6 mg naloxone i.m. were told that
they did not have a clinically recognizable acute withdrawal syn¬
drome and were not allowed to continue in the study.
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TABLE 1

Naloxone Challenge Test -- Rating Scale of Withdrawal*

Symptomatology

Gooseflesh
Vomiting
Tremor
Profuse Sweating
Restlessness
Lacrimation or
nasal congestion
Uncontrollable
yawning

10 MIN
present absent

20 MIN
present absent

30 MIN
present absent

3
3
3
3
2
2

0
0
0
0
0
0

2
0
2
0
2
0
2
0
10
1
0

1
1
1
1
1
1

0
0
0
0
0
0

2

0

10

1

0

*After Wang, et al (Wang 1974) (Weisen 1977) (Wang 1982).
Patients'
symptoms are rated and points assigned at 10, 20, and 30 minutes.
Following Wang (Wang 1984a, 1984b), we automatically assigned points
for later observations if a symptom appeared early, hence symptoms ap¬
pearing at 10 minutes gave the subject either 6 or 4 points, symptoms
first appearing at 20 minutes gave the subject 3 or 2 points.
Ratings followed the administration of naloxone, 0.8 mg i.m..

-
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TABLE 2

Day #1 Clonidine Doses

PREDICTED NCT SCORE
(at 10 minutes)

ORAL CLONIDINE HCl (mg)
8-10 am
2 pm
8 pm

>18

0.3

0.1-0.2

0.2

9-17

0.2

0.1

0.1-0.2

<9 but >0

0.1-0.2

0.1

0.1
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MONITORING OF WITHDRAWAL SYMPTOMS AND VITAL SIGNS

Either an investigator or a research nurse took and recorded
all data.
day.

Vital signs were measured at the start of each study

Sitting and standing blood pressures and heart rate were

measured before, 60 minutes after, and 120 minutes after each
clonidine dose.

The abstinence rating scale, which rates the

presence or absence of 17 signs and symptoms of withdrawal, was
completed by an observer before and 60 minutes after each naltre
xone dose on days 2 and 3.

The patients completed self-rated

visual analogue scales before and 60 minutes after each naltrex¬
one dose.

In addition, Spielberger State Anxiety Scales were

completed by each subject each morning, and each patient complet
ed the Beck Depression Inventory,

the SCL-90,

the Spielberger

Scale and the Rotter Internal/External Locus of Control Scale
during the week before entrance into the study.

DATA ANALYSIS

The number of signs and symptoms reported on the 17 item ab¬
stinence rating scale were totaled, and the mean values of this
score and the analogue scale scores for the ratings completed on
each day were calculated.

These data were used as an index of

the severity of withdrawal signs and symptoms experienced by the
patient.

For every patient,

the percentage of times each indi¬

vidual sign or symptoms was rated as present on the abstinence
rating scale of the total number of ratings completed each day
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was also calculated to determine the symptoms and signs reported
most frequently.

Successful detoxification, defined as completion of the 5 day
protocol and continued naltrexone maintenance for one week, was
investigated as a function of maximum discomfort as measured by
the abstinence rating scale and self-rated analog scales, as well
as initial depressed mood (Beck Inventory), anxiety level (Spielberger Scale), locus of control (Rotter Scale), and score on the
SCL-90.

Attrition rates and time of attrition were also analysed

in terms of the above parameters.

Trend curves were constructed

in which the score on withdrawal scales is plotted against time
in order to quantify patterns of response.

NCT scores were correlated with rate of succesful detoxifica¬
tion,

initial psychological status, maximum daily clonidine and

naltrexone doses,

and level of discomfort as measured by mean

daily scores on the observer-rated abstinence rating scale and
self-rated analogue scales and "withdrawal lines."
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RESULTS

OUTCOME

Sixteen subjects underwent a NCT.

Two had negative challenge

tests and did not continue in the study.
entered the protocol,

Of the fourteen that

twelve successfully completed treatment and

were discharged on maintenance doses of naltrexone.

The two pa¬

tients who failed to complete the study were dissimilar.

The

first had a very low NCT score (score of 6 30 min. after 1.6 mg
naloxone), experienced less discomfort than most patients, but
failed to appear on the morning of the third day.

The second had

a NCT score of 24, and withdrew from the study at noon on the
third day because of discomfort.

On review it became clear that

he received less clonidine on day 3 than other patients with high
NCT scores, and that his symptoms were not as well controlled.
He may have received inadequate doses of clonidine.

The rest of

the data analysis pertains to the twelve patients who completed
the protocol.

One month after they completed the protocol,

five of the

twelve remained in a naltrexone maintenance program, and another
three claimed to be completely drug free (although their claims
were not verified by urine toxicology screens).

Another subject

returned to naltrexone maintenance two months after treatment.
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although he used heroin intermittently following detoxification.
The remaining three were again using opioids regularly one month
after completing the protocol; two of them had entered a metha¬
done maintenance program.

No significant correlations were observed between patient
scores on the psychological tests administered during screening
and NCT score, degree of discomfort during treatment, or total
clonidine dose.

A nonsignificant correlation was observed be¬

tween morning Spielberger State Anxiety Index scores and mean ob¬
server-rated abstinence rating scale scores on days 2 and 3
(r=.60, p<.10; r=.46, p<.20,

respectively).

No correlation was

observed between SSAI scores and daily clonidine doses on these
days (day 2 r=.18, day 3 r=.26).

NALOXONE CHALLENGE TESTS

Two of sixteen subjects had negative challenge tests, bearing
out the need for such provocative testing prior to inclusion in a
research protocol.

Our subjects had a wide range of scores.

Only two patients required 1.6 mg of naloxone to provoke symp¬
toms; most had projected 30 minutes scores greater than 9 10 min¬
utes after 0.8 mg naloxone i.m., and received clonidine at that
time.

Because the test was "stopped" after 10 minutes for nine

subjects, the scores we report may be lower than scores would ac¬
tually have been had the test been allowed to run to completion.
Nevertheless,

some of our patients had high scores.
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In Wang's

series of over 200 patients the median score was in the range
9-12; our median score was 12.

21% of Wang's patients had scores

over twenty; 28% of our patients had scores over twenty.

Wang

recommends initial methadone maintenance doses of over 70 mg/day
for these patients.

CLONIDINE AND NALTREXONE DOSAGE SCHEDULE

Table 3 lists daily clonidine and naltrexone doses.

On day 1,

patients responded well to clonidine after the NCT, experiencing
symptom relief thirty minutes after their first p.o. dose.

Be¬

cause of the NCT, doses were larger than usual clonidine detoxi¬
fication doses.

Clonidine doses rose on days 2 and 3,
naltrexone administration.

the first two days of

On these days the three daily doses

(each of which ranged from 0.1 to 0.3 mg, depending on the pa¬
tient's NCT score and response to clonidine on day 1) were sup¬
plemented by p.r.n. doses if patients had a score of 5 or greater
on the abstinence rating scale.

These p.r.n. doses were usually

0.1 or 0.2 mg, and usually were administered after a naltrexone
dose that had been followed by withdrawal symptoms.

Following

day 3 clonidine doses were tapered rapidly without reemergence of
withdrawal symptoms or signs.

There was a significant correla¬

tion (r=.75, p<.01) between NCT score and total clonidine admin¬
istered (see figure 1).
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Many patients experienced a mild increase in withdrawal symp¬
toms 30 to 45 minutes following their first dose of 1 mg of nal¬
trexone.

All patients with NCT scores > 20 experienced an in¬

crease in symptoms (more than 5 symptoms on the abstinence rating
scale) that responded to p.r.n. doses of clonidine.

These pa¬

tients continued to experience increased symptoms of withdrawal
following naltrexone doses until their cumulative dose of naltre¬
xone exceeded 8 to 10 mg.

Following that point no subjects

claimed to "feel" individual naltrexone doses.

Patients received between 3 mg and 10 mg of naltrexone on the
second day, and between 27 mg and 46 mg on the third day.

There

was a significant correlation (r=-.87, p<.01) between NCT score
and naltrexone tolerated on the second day (figure 2).

On the

fourth day all subjects received at least 50 mg of naltrexone
without induction of withdrawal symptoms.

Day 5 was usually a Friday; patients received 150 mg naltrex¬
one to ensure opioid blockade over the weekend.

One patient did

not return the following week, but the remaining eleven completed
an additional week of maintenance naltrexone as part of the pro¬
tocol.

Of these eleven, one patient had mild "stomach cramps"

and anorexia on the mornings of naltrexone administration; he
continued on naltrexone and was asymptomatic after two weeks of
maintenance.

The others had no such symptoms sometimes associat¬

ed with naltrexone induction (Martin 1973)
hen 1977),

(Hollister 1981)

(Bra-

(Sideroff 1978) and no subjects had reemergence of

withdrawal symptoms.
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Patients were given chloral hydrate,
time, as needed for insomnia.
dose of chloral hydrate.

1 gram, one dose at a

Eleven patients took at least one

Seven patients complained that chloral

hydrate did not relieve their insomnia, and received flurazepam,
15 to 30 mg p.o. per night as needed after the second night.

28

TABLE 3

Clonidine and Naltrexone Dosage Schedule (Means and SDs)

Day#

Naltrexone HCl, mg/day
SD
X

Clonidine HCl, mg/day
X
SD

0

0.5

0.2

2

8

3

1.1

0.5

3

40

7

0.6

0.3

4

50

0

0.3

0.3

5

150

0

0.2

0.2

6

0

0.1

0.1

7

0

0.0

o
o

100

0.0

10

100

0.0

12

100

0.0

8*

CNJ

0

o

1

* One subject did not return for the second week
and is not included in days 8, 10, and 12.
° Two subjects self-administered 0.1 mg clonidine
on day #7.
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FIGURE 1
M_ CLONIDINE VS. NCT SCORE
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TOTAL CLONIDINE mg/5 day protocol

Figure 1 - Total Clonidine vs. NCT Score:

Correlates the total

clondine dose administered to each patient with that patient's
NCT score.

The one patient who completed the protocol who re¬

ceived 1.6 mg naloxone during the NCT is excluded,

so that all

NCT scores plotted are for 0.8 mg naloxone,

Least squares

regression is shown.

i.m..

r = .75, p < .01 by 2 tailed t test, 9 de¬

grees of freedom.
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FIGURE 2
NALTREXONE VERSUS NOT SCORE

#2
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mg NALTREXONE, DAY 2

Figure 2 - Day #2 Naltrexone Dose vs. NCT Score:

Correlates the

total naltrexone dose administered to each patient on day #2 with
that patient's NCT score.

The one patient who completed the pro¬

tocol who received 1.6 mg naloxone during the NCT is excluded.
Least squares regression is plotted.

r = -.87, p <

tailed t test, 9 degrees of freedom.

Maximum possible naltrexone

dose on day #2 was 10 mg.
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.01 by two

SIGNS AND SYMPTOMS OF WITHDRAWAL
The treatment regimen effectively suppressed signs and symptoms
of withdrawal.

On no day was the mean number of signs and symp¬

toms greater than 3 out of the 17 included in the abstinence rat¬
ing scale (figure 3).
mild in nature.

Often the symptoms that were reported were

Patient ratings of analogue scales (table 4) and

"withdrawal lines"

(figure 4) indicate that the withdrawal pro¬

cess was relatively comfortable for the majority of patients.
The high percentage of patients who completed the protocol sug¬
gests that the treatment was efficacious.

There was a correlation between NOT score and mean number of
abstinence symptoms.

Patients with NOT scores > 20 experienced

significantly more symptoms, with a mean of over 5 symptoms on
day 2 (figure 3)

(treatment F(l,90)=16.9, pc.Ol).

These patients

experienced a higher degree of subjective discomfort, as evi¬
denced by their ratings on the 100 mm "withdrawal line"
4)

(treatment F(1,70)=23.4, pc.Ol).

(figure

Patients with NCT scores >

20 reported significantly higher levels of subjective withdrawal
discomfort on days 2 through 8.

The most prominent symptom in

this group was muscular aching that provoked some distress.

The

final patient to complain of persistent muscular aching was pre¬
scribed diazepam 10 mg p.o. b.i.d.
treatment of insomnia)

(including an evening dose for

that markedly relieved the symptom.

For all patients the most persistent symptoms were restless¬
ness, anxiety, muscular aching, craving,
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insomnia, and hot and

cold flashes (table 5).
ported were mild.

From day 5 onward symptoms that were re

Analogue self-rating scales showed moderate

positive trends during treatment (table 4).

Patients were questioned and observed for symptoms and signs
of a clonidine withdrawal syndrome (Hansson 1975)
(Pettinger 1975).

(Stelzer 1976)

No significant "rebound" hypertension was ob¬

served when clonidine doses were tapered (table 6).

Three pa¬

tients did note increased restlessness: one on day 5, another on
days 4 and 5, and the third on days 5 and 6.

All three also not

ed insomnia on those days, which responded to prescribed medica¬
tion.

Two of the three said they "felt like I'm speeding;" none

were distressed by these symptoms, and all reported that their
symptoms resolved as their clonidine taper was slowed.

These

symptoms could also be explained as opioid withdrawal symptoms
inadequately treated because the dose of clonidine had been re¬
duced too quickly.
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TABLE 4

Changes in Patient-Rated Scales* During Treatment

Unpleasantness
DAY#
Energy
High/Low

Nervousness
Uninvolvement
Irritability

1°

2.8

3.5

3.2

4.0

3.6

2.0

2

3.2

2.8

2.7

3.2

3.1

1.1

3

3.2

2.6

2.7

3.3

2.8

1.4

4

3.6

2.8

3.8

3.3

3.2

1.3

5

3.4

2.7

3.5

3.0

2.7

0.8

8

4.1

1.8

5.2

3.3

2.7

0.9

10

3.5

2.6

4.6

2.9

2.6

1.4

Changes over time not statistically significant.
*These scales were rated by patients, using a seven point scale with
1 as low and 7 as high.
°Day #1 scales were completed on arrival at clinic, before medications
were given or NCT begun.

-
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TABLE 5

Effect of Treatment on 17 Signs and Symptoms of Withdrawal

DAY #
1

2

3

4

5

8

10

12

92
83
92
75
75
92
75
92

26
21
29
11
47
18
5
21

49
37
41
18
53
19
9
31

29
24
30
8
33
18
2
18

33
19
27
22
17
20
0
14

16
4
38
38
25
8
0
8

25
0
0
8
0
0
0
0

8
0
0
8
0
0
0
0

16
0
0
8
0
8
8
8

67
33
58
50
42
100
17
8
33

5
3
0
0
26
0
3
0
5

2
3
9
1
9
0
0
0
1

3
1
3
0
12
0
0
2
0

0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0

NCT
Subjective symptoms*
Craving
Anxiety
Restlessness
Insomnia
Muscular aching
Anorexia
Nausea
Hot and cold flashes
Objective symptoms0
Rhinorrhea
Tremors
Perspiration
Yawning
Yen for sleepGooseflesh
Vomiting
Diarrhea
Lacrimation

Numbers indicate the percentage of positive symptom reports of
all ratings done each treatment day.
Day #1 values include
all ratings completed two or more hours after NCT.
^Determined by responses to specific questions.
determined by direct observation.
-•This sign may have been overrated because of clonidine's
sedating effect.
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FIGURE 3
MEAN # OF ABSTINENCE SX AND SIGNS PER DAY
maximum # of sx and signs = 17

Figure 3 - # Of Abstinence Symptoms and Signs per Day:

Corre¬

lates mean number of signs and symptoms per patient per day,

as

rated on the 17 item observer-rated abstinence rating scale, with
day number. Curves represent mean scores for patients with NCT
scores > or < 20.

The two plots are significantly different as

analyzed by 2-way ANOVA for repeated measures (treatment
F(1,90)=16.9, pc.Ol; repeated measure F(9,90)=17.4, pc.Ol; inter¬
action F(9,90)=4.5, pc.Ol).

The mean score for the NCT > 20 pop¬

ulation is significantly different (pc.05) from the NCT c 20 pop¬
ulation, by 2-tailed t test, on days 1 through 8, n values as
listed in the legend.

39

FIGURE 4
WITHDRAWAL LINE SCORES PER DAY
100
90
80
70
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50
40

\

\

\

\
\

30
20
10

Legend
A NCT GREATER THAN 20 N=3
X NCT LESS THAN 20

0

DAY #

N=9

Figure 4 - Mean Withdrawal Line Scores per Day:
withdrawal line scores with day number.

Correlates mean

The "withdrawal line" is

a horizontal 100 mm line that functions as an analogue scale; the
left end is labelled "0-no withdrawal" and the right end is la¬
belled "100-severe withdrawal".

Curves represent mean scores for

patients with NCT scores > or < 20.

The two plots are signifi¬

cantly different as analyzed by 2-way ANOVA for repeated measures
(treatment F(1,70)=23.4, pc.Ol; repeated measure F(7,70)=14.8,
pc.Ol; interaction F(7,70)=3.6, pc.Ol).

The mean score for the

NCT > 20 population was significantly different (p<.05) from the
NCT < 20 population, by 2-tailed t test, on days 2 through 8, n
values as listed in the legend.

41

BLOOD PRESSURE AND HEART RATE CHANGES

Table 6 summarizes changes in blood pressure and heart rate
during treatment.

Clonidine lowered blood pressure significantly

(treatment F(5,55)~22.0, p<.01 for systolic BP,
diastolic BP).

12.5, pc.Ol for

There were no syncopal episodes during the course

of treatment, however most patients reported dizziness on stand¬
ing during days 2 and 3.

Clonidine doses were held or tapered if

blood pressure fell below 80/60 or if the patient noted orthos¬
tatic symptoms; typically, when withdrawal symptoms began to re¬
appear, blood pressure increased, and patients were again given
medication.

Dizziness was not present on the fourth day or

thereafter.

Patients with NCT scores > 20 did not have signifi¬

cantly larger decreases in blood pressure or heart rate than did
patients with NCT scores < 20 (treatment F(l,50)=2.99 for systol¬
ic BP, 0.4 for diastolic BP).

There was no constant relationship

between NCT score and occurence of orthostatic symptoms.

Overall

fluctuations in standing and supine heart rate were not signifi¬
cant (F(5,41)=1.37 for standing heart rate,

1.83 for supine heart

rate).

On days 1, 2, and 3, all patients were brought to clinic and
driven home by a "significant other."
to remain home these evenings,
take hot showers.

Patients were instructed

to sit when urinating,

and not to

An investigator was "on call" each evening to

respond to questions.
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Patients noted sedation on the second and third day, another
clonidine side effect.

This sedating effect is reflected in the

"yen for sleep" ratings in Table 5.
monly reported clonidine side effect.

Dry mouth was the other com¬
One patient noted a per¬

sistent metallic taste while taking clonidine.
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TABLE 6

Changes in Standing BP and Pulse during Treatment*

DAY#

INITIAL

BP, mm HG
systolic
diastolic
SD
X
SD
X
111

11

74

7

66

9

81

9

1°

97 #

15

70

13

2

85 #

13

62 #

10

65

11

81

14

3

85 #

14

61 #

10

59

7

83

15

4

97 #

14

68 #

11

68

6

92 #

15

73

7

83

13

5

105

13

73

7

8

115

11

78

6

10

111

13

74

5

*

#

°
-■

HEART RATE, Beats/min
Standing
Lying
SD
X
SD
X

Overall changes in systolic and diastolic BP were significant
as analyzed by 1-way ANOVA for repeated measures (treatment
F(5,55)=22.0, pc.Ol for systolic BP, 12.5, p<.01 for diastolic
BP).
Fluctuations in heart rates were not significant (treat¬
ment F(5,41)=1.37 for standing heart rate, 1.83 for supine
heart rate) .
Values for each treatment day are the mean (+-SD) for all
measurements except for "INITIAL", which is the mean for all
subjects of two BP measurements taken at least three days
apart prior to each subject's entry into the study.
Initial heart rates are measurements from morning of day #1,
prior to medication or NCT.
Significantly different from "INITIAL" (pc.Ol) by two tailed
t test, with n=24 for INITIAL BP means and n=ll for heart
rate means.
Measurements are included that were > two hours after NCT.
Standing measurements reflect orthostatic effects; supine
measurements were used to eliminate orthostatic effects and
uncover underlying bradycardia (a clonidine side effect).
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COMPLIANCE

Subjects appeared to comply well with instructions regarding
clonidine self-administration.

They were given one day's (or

evening's) supply of clonidine on leaving clinic, and they re¬
turned pill bottles each morning and accounted for all clonidine
taken.

Usually patients were given 0.1 mg to 0.3 mg clonidine

for p.r.n.

use,

in addition to prescribed doses; several pa¬

tients consistently woke in the early morning hours with with¬
drawal symptoms that responded to a p.r.n. dose of clonidine.

One patient self-administered intravenous heroin and cocaine
on the evening of the first day, and another used intravenous
heroin on the second evening.

They were allowed to continue in

the protocol; both received maximum doses of naltrexone without
adverse effects, and had low mean abstinence rating scale scores
Both had initial NCT scores < 20.
cology screens sent on the first,

All patients had urine toxi¬
third, and fifth mornings.

These were unremarkable, except for the two incidents mentioned.
Another subject self-administered intravenous heroin on the sev¬
enth day, when he had already taken maintenance doses of naltrex
one.

He reported that the heroin had no effect.
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COMPLICATIONS

The one subject who entered the study from methadone mainte¬
nance had a difficult course and did not complete the protocol.
She had been maintained on methadone for two years, and used a
TENS unit for treatment of back pain following an automobile ac¬
cident one year prior to entering our protocol.

Her daily metha¬

done dose (originally 80 mg) had been rapidly tapered to 25 mg,
and she was very anxious about detoxifying, but wanted to try it
so that her fiance would not know she was on methadone mainte¬
nance.

Her withdrawal symptoms were not adequately controlled,

despite clonidine doses in excess of previously published dosage
ranges established by the Connecticut Mental Health Center inpa¬
tient clonidine-naltrexone protocol (Charney, et al,

1982).

On

the evening of the second day she withdrew from the study, having
received 3 mg naltrexone and 3.0 mg clonidine by 6 pm.

At that

time her standing blood pressure was 118/88, with a pulse rate of
60.

She received 20 mg methadone and presented 4 hours later

with headache, a pulse of 27 beats per minutes, and a systolic
blood pressure of 180.

EKG showed irregular sinus bradycardia

without heart block or escape rhythms.

Optic discs were flat and

sharp, and neurological examination was nonfocal.
report withdrawal symptoms.

She did not

She was subsequently hospitalized

and observed until her pulse rate and blood pressure returned to
normal; no medical treatment was required.

Retrospectively she

reported that she had been taking large doses of Darvocet (ob¬
tained by prescription for relief of back pain) at home during
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the past month,

to relieve discomfort associated with methadone

taper. She also reported that she had ingested 150 mg illicitly
obtained flurazepam on the evening of day 1, and flurazepam,

dia¬

zepam, and Darvocet tablets on the evening of day 2 after receiv¬
ing methadone.

Bradycardia and hypertension are symptoms of clo-

nidine overdose (Andserson 1981)

(Rotellar 1981), and the

patient's course was consistent with clonidine effect unopposed
by withdrawal following methadone administration, but the large
self-administered doses of benzodiazapenes (as well as opioids,
and possibly other compounds) cloud interpretation of the event.
This experience highlights the potential problem of patients'
self-administering large doses of illicit medications during out¬
patient treatment.

Other candidates have yet to enter our proto¬

col from methadone maintenance; such patients have been success¬
fully treated in the past as inpatients at the Connecticut Mental
Health Center.
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DISCUSSION

COMMENT

This clonidine-naltrexone regimen enabled 12 of 14 heroin
users to completely withdraw from opioids in 5 days, while simul¬
taneously initiating naltrexone maintenance.

This success rate

of 86% compares favorably to previous experience with gradual me¬
thadone taper (13 out of 24 patients, 35%)

(Dorus 1981) and

treatment with clonidine alone (4 out of 11 patients, 36%)
ton 1980b).

(Wash-

It is comparable to the experience of Charney, et al

(Charney 1982) who used a similar regimen with 11 inpatients.
Comparison with this earlier study, which used identical rating
scales, generally reveals a lesser incidence of symptoms in the
current study; all patients in the earlier study were withdrawn
from methadone maintenance.

Since our protocol simultaneously began naltrexone mainte¬
nance,

the 86% who completed the protocol also successfully began

naltrexone maintenance therapy.

Only one of the twelve experi¬

enced symptoms sometimes associated with the first 10 days of
naltrexone treatment (Brahen 1977).

This rate of successful nal¬

trexone induction compares well to previously published studies
which report successful induction rates of non-opioid dependent
outpatients ranging from 37% to 50% (Callahan 1976)
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(Resnick

1980)

(Kosten 1984).

Our data support the previously suggested

hypothesis that clonidine may be an effective adjunct to initia¬
tion of naltrexone maintenance, even for those outpatients who
are no longer opioid dependent (Kosten 1984)

(Dorus 1982).

Clonidine and naltrexone worked well in the outpatient set¬
ting.

Patients reported mild withdrawal symptoms that did not

interfere with treatment.
seen.

Signs of opioid withdrawal were rarely

While patients felt "under the weather" on days 2 and 3,

on days 4 and 5 they rarely had significant complaints.

Standing

blood pressures were lowered, often producing some orthostatic
symptoms on days 2 and 3 without clinical problems.

Flexible

dosage schedules allowed us to tailor individual treatment so as
to minimize symptoms of withdrawal.

Limitations on outpatient treatment emerged.

Of the two pa¬

tients who withdrew from the study, one was relatively asympto¬
matic; perhaps this subject would have remained in treatment had
he been hospitalized and removed from the mileu of drug abuse.
In addition, one patient was hospitalized and observed for signs
of clonidine overdose following her withdrawal from the study,
administration of methadone, and self-administration of opioids
and benzodiazapenes.

Although this patient did not require medi¬

cal treatment, her case illustrates the potential risks of con¬
current illicit drug use.

Patients who leave a clonidine-naltre¬

xone regimen before receiving enough naltrexone to establish
opioid blockade, and who subsequently receive opioids, may devel-
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op signs of clonidine overdose if they have been given large dos¬
es of clonidine.

Thus large daily doses of clonidine (> 3.0 rag

over 24 hr) should be administered with caution to outpatients,
especially if they are likely to withdraw from treatment and re¬
sume opioid use prior to receiving blockading doses of naltrex¬
one.

Two other subjects who completed the protocol used illicit

drugs intercurrently,

apparently not affecting the course of

their treatment.

The patient who experienced medical complications came to our
protocol from methadone maintenance.

Given the results of Char-

ney, et al, who successfully treated methadone maintained pa¬
tients with a similar clonidine-naltrexone regimen (Charney
1982),

the poor control of this patient's symptoms was probably

not a function of her previous methadone maintenance, but rather
of her anxiety and illicit drug use.

Nevertheless, outpatient

treatment of methadone maintained patients with this regimen re¬
quires additional investigation.

Naloxone challenge tests established that patients were indeed
dependent on opioids.

Two subjects (12%) had a negative NCT.

One of these two subjects had claimed to use large quantities of
heroin daily and was expected to have a high score; following the
test he admitted that he actually used much smaller amounts of
opioids.

Previously reported incidences of negative challenge

tests range from 3% (Blachly 1973) to 33% (Judson 1980).
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Correlations were observed between NCT score and total clonidine administered, patient discomfort as measured by patient-rat¬
ed analogue "withdrawal lines", and patient discomfort as meas¬
ured by the observer-rated abstinence rating scale.

An inverse

correlation was observed between NCT score and day 2 naltrexone
doses.

These findings suggest that the clonidine-naltrexone reg¬

imen most effectively suppresses withdrawal symptoms in less se¬
vere addictions.

However, even patients with NCT scores over 20

(who are the 20% with the most severe addictions in Wang's se¬
ries)

(Weisen 1977)

(Wang 1982) tolerated the protocol, generally

experiencing more symptoms and receiving naltrexone in a more
gradual fashion.

These patients had more symptoms of withdrawal

despite receiving higher doses of clonidine. This suggests either
that clonidine in non-toxic doses has a limited capacity to slow
central noradrenergic activity during precipitated withdrawal, or
that other central and peripheral effects of opioids (Redmond 84)
can provoke withdrawal symptoms not associated with noradrenergic
activity.

Diazepam appeared to be of use in ameliorating the

persistent muscle tension and aching that was the most prominent
symptom experienced by these patients.

(An alternative explana¬

tion of these findings is that the severity of the symptoms en¬
countered by the patient during the NCT affected their expecta¬
tions for the subsequent withdrawal process and so altered their
subjective experience.

This hypothesis would not, however, ac¬

count for these patients' need for higher clonidine doses or more
gradual naltrexone introduction.)
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If this regimen is employed without a NCT,

day 1 clonidine

doses will be lower, and subsequent clonidine and naltrexone dos¬
es must be titrated to patient symptoms with p.r.n. clonidine
doses on days 2 and 3, as outlined in the "methods" and "results"
sections.
day,

Alternatively, naltrexone could be begun on the first

following an initial clonidine dose of 0.1 to 0.3 mg in the

morning,

shortening the protocol by one day.

The naloxone admin¬

istered during the NCT, by inducing abrupt withdrawal, may have
had a theraputic as well as diagnostic effect.

This effect was

probably small given the short half-life of naloxone.

Why does naltrexone speed the time course of withdrawal, en¬
abling patients to discontinue clonidine by their sixth day of
treatment?

As outlined in the introduction, administration of

naltrexone to opioid-dependent animals rapidly reverses morphineinduced increases in the number of brain alpha-2 and beta adren¬
ergic binding sites (Cedarbaum 1977)

(Hamburg 1981).

In addi¬

tion, clonidine suppresses naltrexone-precipitated withdrawal
signs and symptoms, but increased doses of clonidine are required
(Charney 1981)

(Charney 1982).

Thus naltrexone probably speeds

the process of withdrawal by rapidly reversing opioid-induced
central noradrenergic hypersensitivity.

Interestingly, patients

withdrawing from heroin required clonidine until their fifth or
sixth day, as did patients withdrawing from methadone in the in¬
patient study of Charney, et al (Charney 1982).

A clonidine-nal-

trexone protocol appears to equalize the length of the heroin and
methadone withdrawal syndromes, possibly by displacing opioids
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from binding sites and so eliminating the effect of opioid halflife on the time course of central noradrenergic renormalization.
Naltrexone also increases opioid receptor number and functional
sensitivity (Lahti 1978)

(Schulz 1979), and might reverse the hy¬

pothesized exogenous opioid-induced deficiency in endogenous
opioid function (Kosterlitz 1975)

(Goldstein 1977).

This action

could account for rapid resolution of withdrawal symptoms in this
context, but only if the degree of opioid blockade achieved with
50 mg naltrexone per day does not block endogenous opioid ac¬
tions.

Acutely,

50 mg naltrexone blocks the effects of as much

as 240 mg morphine (Martin 1973), and tolerance to naltrexone's
antagonistic effect does not develop after chronic administration
(Kleber 1985).

IMPLICATIONS
This study demonstrates that a clonidine-naltrexone regimen is an
effective,

safe,

and rapid means of treating heroin withdrawal in

a supervised outpatient/day setting.

The protocol we have used

requires patient visits to clinic on the mornings of days 1, 4,
and 5, and patient presence in clinic on days 2 and 3.

It also

prevents patients from working or driving on the first two days
of naltrexone administration.

Naltrexone was approved by the Food and Drug Administration in
November 1984, and is marketed under the trade name of "Trexan."
Thus this technique can be more widely used for heroin detoxifi¬
cation (although clonidine is still an experimental treatment of

53

opioid withdrawal).

Trexan is supplied in scored 50 mg tablets,

therefore use of the protocol described in this paper would re¬
quire preparation of "powder packets" of pulverized tablets.
ternatively,

Al¬

tablets could be fractured twice and an initial dose

of 12.5 mg naltrexone given.
dose larger than 3 mg.

We have not administered an initial

However, patients with NCT scores below

20 (and certainly those with scores below 15) have,

in general,

tolerated their initial doses of naltrexone so well that a first
dose of 12.5 mg is conceivably appropriate for them.

If this

larger dose was used, naltrexone could be administered in one or
two daily doses on days 2 and 3, and patients could leave clinic
earlier on these days, as well.

Investigation of a simplified

protocol, and treatment of methadone maintained patients with an
outpatient protocol, are the next logical steps for this outpa¬
tient research.

This protocol provided 11 of 12 patients with a simultaneous
smooth induction of naltrexone maintenance, and no patients noted
symptoms of a prolonged abstinence syndrome during the week fol¬
lowing treatment.

The possible value of this treatment method in

improving the long-term prognosis of opioid abusers awaits inves¬
tigation in well controlled studies comparing clonidine and nal¬
trexone to clonidine alone and slow methadone taper.

The time

course and patient comfort of this regimen make it a useful,

at¬

tractive, and efficacious outpatient method of treating the acute
opioid withdrawal syndrome.

54

NOTES

Aghajanian GK:

Tolerance of locus coeruleus neurones to morphine

and suppression of withdrawal response by clonidine.

Nature

1978; 276:186-188.

Anderson RJ et al:

Clonidine overdose: report of six cases and

review of the literature.

Annals of Emergency Medicine 1981;

10(2):107 -112.

American Psychiatric Association:

Diagnostic and Statistical

Manual of Mental Disorders, Third Edition.
D.C.,

1980, pp.

163-173.

Bird SJ, Kuhar MJ:
locus coeruleus.

Iontophoretic application of opiates to the
Brain Res 1977; 122:523-533.

Berle B, Nyswander M:
addiction.

APA, Washington,

Ambulatory withdrawal treatment in heroin

NY State J Med 1964; 64:1846-1948.

Blachly PH:

Naloxone for disagnosis in methadone programs.

JAMA

1973; 224:334-335.

Blachly P, Casey D, Marcel L, et al:

Rapid detoxification from

heroin and methadone using naloxone,

in Senay E, Shortz V, Alk-

esne H (eds):

Developments in the Field of Drug Abuse Cambridge,

Mass, Schenkman Publishing,

1975, pp 327-336.

55

Brahen LS, et al:

Naltrexone and cyclazocine.

Arch Gen

Psychiatry 1977; 34:1181-1184.

Buccafusco JJ:

Cardiovascular changes during morphine withdrawal

in the rat: effects of clonidine.

Pharm Biochem and Behavior

1983; 18:209-215.

Callahan EJ, et al:

Comparison of two naltrexone treatment pro¬

grams: naltrexone alone versus naltrexone plus behavior therapy,
in Julius D, Renault P (eds). Narcotic Antagonists: Naltrexone,
NIDA Research Monograph 9,

1976, pp.

Cedarbaum JM, Aghajanian GK:

163-171.

Catecholamine receptors on locus

coeruleus neurons: pharmacological characterization.

Eur J Phar-

mac 1977; 44:375-385.

Charney DS, Sternberg DE, Kleber HD, et al:

The clinical use of

clonidine in abrupt withdrawal from methadone.

Arch Gen Psychia¬

try 1981; 38:1273-1277.

Charney DS, Riordan CE, Kleber HD, et al:
one.

Clonidine and naltrex¬

Arch Gen Psychiatry 1982; 39:1327-1332.

Crawley JN, Laverty RN, Roth RH:

Clonidine reversal of increased

norepinephrine metabolite levels during morphine withdrawal.

Eur

J Pharmacol 1979; 57:247-255.

Dorus W, Senay EC, Showalter CV:
methadone.

Short term detoxification with

Ann NY Acad Sci 1981; 362:203-216.

56

Dorus W:

Withdrawal from opioid drugs: a review of techniques

and outcomes,
tients;,

in Craig RJ, Baker SL (eds):

Drug dependent pa¬

treatment and research, Charles C Thomas, Springfield IL,

1982, pp. 7-36.

Edwards G, Arif A, Hodgson R, et al:

Nomenclature and classifi¬

cation of drug- and alcohol-related problems:

a WHO Memorandum.

Bulletin of the World Health Organization 1981; 59(2):225-242.

Gold MS, Redmond DE Jr, Kleber HD:
wal.

Clonidine in opiate wtihdra-

Lancet 1978(a); 1:929-930.

Gold MS, Redmond DE Jr, Kleber HD:
withdrawal symptoms.

Clonidine blocks acute opiate

Lancet 1978(b); 2:599-602.

Gold MS, Pottash AC, Sweeney DR, et al:
clonidine.

JAMA 1980; 243:343-346.

Goldstein A, Cox BM:
and brain).

Gunne LM:

Opiate withdrawal using

Opioid peptides (endorphins in pituitary

Psychoneuroenocrinology 1977; 2:11-16.

Noradrenaline and adrenaline in the rat brain during

acute and chronic morphine administration and during withdrawal.
Nature 1959; 184:1950-1951.

Hamburg M, Tallman JF:

Chronic morphine administration increases

the apparent number of alpha-2 adrenergic receptors in rat brain.
Nature 1981; 291:493-495.

57

Hansson L, et al:

Blood pressure crisis following withdrawal of

clonidine with special reference to arterial and urinary catecho¬
lamine levels, and suggestions for acute management.

Amer Heart

J 1975; 85:605.

Hollister LE,

et al:

Aversive effects of naltrexone in subjects

not dependent on opiates.

Drug and Alcohol Dependence 1981;

8:37-41.

Judson BA, et al:

The naloxone test for opiate dependence.

Clin

Pharm Ther 1980; 27:492-501.

Judson BA, Carney TM, Goldstein A:

Nalrexone treatment of heroin

addiction: efficacy and saftey in a double-blind dosage compari¬
son.

Drug Alcohol Dep 1981; 7:325-346.

Kleber HD, Riordan CE:
historical review.

The treatment of narcotic withdrawal: a

J Clin Psychiatry 1982; 43:6:30-34.

Kleber HD, Kosten TR, Gaspari J, Topazian M:
opioid antagonism of naltrexone.

Korf J, Bunney BS, Aghajanian GK:

Nontolerance to the

Biol Psychiatry 1985; 20:66-72.

Noradrenergic neurons: Mor¬

phine inhibition of spontaneous activity.

Eur J Pharmacol 1974;

25:165-169.

Kosten TR, Kleber HD:
cotic antagonists.

Strategies to improve compliance with nar¬

Am J Drug Alcohol Abuse 1984; 10(2) :249-266.

58

Kosterlitz HW, Hughes J:
enkephalin,

Some thoughts on the significance of

the endogenous ligand.

Kuiland AA, McCabe L:

Life Sci 1975; 17:91-96.

Rapid detoxification of the narcotic ad¬

dict with naloxone hydrochloride:

a preliminary report.

Clin

Pharmacol 1975; 16:66-75.

Lahti R, Collins RH:

Chronic naloxone results in prolonged in¬

crease in opiate binding sites in brain.

Eur J Pharmacol 1978;

51:185-186.

Laverty R, Roth RH:

Clonidine reverses the increased norepineph¬

rine turnover during morphine withdrawal in rats.

Brain Res

1980; 182:482-485.

Llorens C, Martres MP, Baudry M, et al:

Hypersensitivity to no¬

radrenaline in cortex after chronic morphine:
erance and dependence.

relevance to tol¬

Nature 1978; 274:603-605.

Martin WR, Jasinski DR, et al:
treatment of heroin dependence.

Naltrexone, an antagonist for the
Arch Gen Psychiatry 1973;

28:784-791.

Pettinger WS:

Clonidine--a new antihypertensive drug.

New Engl

J Med 1975; 293:1179.

Redmond DE Jr, Huang YH, Snyder DR, Maas JW:

Behavioral effects

of stimulation of the nucleus locus coeruleus in the stump-tailed
monkey.

Brain Research 1976; 116:502-510.

59

Redmond DE Jr:

Alterations in the function of the nucleus locus

coeruleus: A possible model for studies of anxiety,
Usdin E (eds):

in Hanin I,

Animal Models in Psychiatry and Neurology.

York, Pergamon Press,

New

1977, pp 293-306.

Redmond DE Jr, Gold MS, Huang YH:

Enkephalin acts to inhibit lo¬

cus coeruleus mediated behaviors.

Neurosci Abst 1978; 4:413.

Redmond DE Jr:

Clonidine and the primate locus coeruleus: evi¬

dence suggesting anxiolytic and anti-withdrawal effects,

in Lai

H, Fielding S (eds), Psychopharmacology of Clonidine, Alan R.
Liss Inc, New York,

1981; pp 147-153.

Redmond DE Jr, Krystal JH:
from opioid drugs.

Multiple mechanisms of withdrawal

Annual Rev Neurosci 1984; 7:443-478.

Resnick RB, Kentenbaum RS, Washton A, et al:

Naloxone-precipi¬

tated withdrawal: A method for rapid induction onto naltrexone.
Clin Pharmacol Ther 1977; 21:409-413.

Resnick RB, Washton AM, et al:

Psychotherapy and Naltrexone in

Opioid Dependence, paper presented at Committee on Problems of
Drug Dependence,

1980.

Riordan CE, Kleber HD:
dine and naloxone.

Rotellar JAO, et al:

Rapid opiate detoxification with cloni¬

Lancet 1980; 1:1079-1080.

Clonidine in thousand-fold overdose.

cet 1981; 1:1312.

60

Lan¬

Schulz R, Wuster M, Herz A:

Supersensitivity to opioids folowing

the chronic blockage of endorphin action by naloxone.

Nauyn

Schmiedebergs Arch Pharmacol 1979; 306:93-96.

Senay EC, et al:

Withdrawal from methadone maintenance.

Arch

Gen Psychiatry 1977; 34:361-367.

Sideroff SI, et al:

Craving in heroin addicts maintained on the

opiate antagonist naltrexone.

Am J Drug Alcohol Abuse 1978;

5(4):414-423.

Silsby H, Tennant FS Jr:

Short-term, ambulatory detoxification

of opiate addicts using methadone.

Int J Addict 1974;

9(1) : 167-170.

Sparber SB, Meyer DR:

Clonidine antagonizes naloxone-induced

suppression of conditioned behavior and body weight loss in mor¬
phine-dependent rats.

Pharm Biochem and Behavior 1978;

9:319-325.

Stelzer FP, et al:

Late toxicity of clonidine withdrawal.

New

Engl J Med 1976; 294:1182.

Tseng LF, Loh HH, Wei ET:
drawal signs in the rat.

Effects of clonidine on morphine with¬
Eur J Pharmacol 1975; 30:93-99.

Uhde TW, Redmond DE Jr, Kleber HD:

Clonidine suppresses the

opioid abstinence syndrome without clonidine-withdrawal symptoms:
a blind inpatient study.

Psychiatry Res 1980; 2:37-47.

61

Vasquez BJ, Overstreet DH, Russell RW:

Psychopharmacological ev¬

idence for increase in receptor sensitivity following chronic
morphine treatment.

Wang RI, et al:
pendence.

Rating the presence and severity of opiate de¬

Clin Pharm Ther 1974; 16(4) :653-658.

Wang RI, et al:
tion.

Initial methadone dose in treating opiate addic¬

Int J Addict 1982; 17(2) :357-363.

Wang RI:

Issues and problems in the toxicologic analysis of

drugs of abuse,
tients,

Psychopharmacologia 1974; 38:287-302.

in Craig RJ, Baker SL (eds):

Drug dependent pa¬

treatment and research, Charles C Thomas, Springfield IL,

1982, pp.235-259.

Wang RI, personal communication,

Washton AM, Resnick RB:
detoxification.

1984(b).

Clonidine versus methadone for opiate

Lancet 1980(a); 2:1297.

Washton AM, et al:

Clonidine for opiate detoxification: outpa¬

tient clinical trial.

Washton AM, Resnick RB:

Am J Psych 1980(b); 137:1121-1122.

Clonidine vs methadone for opiate detox¬

ification: double blind outpatient trials,

in Harris LS (ed):

Problems of Drug Dependence: NIDA Research Monograph Dept of
Health and Human Services publication (ADM)81-1058,#34,1981, pp
89-94.

62

Weisen RL, et al:
tic aid.

The saftey and value of naloxone as a therapu-

Drug and Alcohol Dep 1977; 2:123-130.

Wilson BK, Elms RR, Thomson CP:
extended detoxification.

Low-dosage use of methadone in

Arch Gen Psychiatry 1974; 31:233-236.

Wilson BK, Elms RR, Thomson CP:

Outpatient vs. hospital metha¬

done detoxification: an experimental comparison.
1975; 10(1):13-21.

63

Int J Addict

YALE MEDICAL LIBRARY
Manuscript Theses

Unpublished theses submitted for the Master’s and Doctor’s degrees and
deposited in the Yale Medical Library are to be used only with due regard to the
rights of the authors.
Bibliographical references may be noted, but passages
must not be copied without permission of the authors, and without proper credit
being given in subsequent written or published work.

This thesis by
has been
used by the following persons, whose signatures attest their acceptance of the
above restrictions.

NAME AND ADDRESS
^ uurvj

DATE

Hljh
/V

t>r)

UL*'v

A

?(7

